Evidence map›Paper›PMID 40333672›Full record

ArticleMolecules (Basel, Switzerland)2025

Cytotoxicity Comparison of

Sahar Nosrati Shanjani, Monika Łyczko, Rafał Walczak, Przemysław Koźmiński, Emilia Majka, Jerzy Narbutt, Wioletta Wojdowska, Agnieszka Majkowska-Pilip, Aleksander Bilewicz

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sahar Nosrati ShanjaniInstitute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Monika ŁyczkoInstitute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Rafał WalczakInstitute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.ORCID 0000-0002-0308-7223
Przemysław KoźmińskiInstitute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.ORCID 0000-0003-0471-6949
Emilia MajkaInstitute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Jerzy NarbuttInstitute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Wioletta WojdowskaNational Centre for Nuclear Research, Sołtana 7/3, 05-400 Otwock, Poland.
Agnieszka Majkowska-PilipInstitute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.ORCID 0000-0001-9449-6411
Aleksander BilewiczInstitute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.ORCID 0000-0003-2490-3303

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Auger electrons are low-energy, high-linear-energy-transfer particles that deposit their energy over nanometers distances. Their biological impact depends heavily on where the radionuclide is localized within the cell. To verify the hypothesis that the cell membrane may be a better molecular target than the cytoplasm in Auger electron therapy, we investigated whether the radiotoxicity of

Indexed as

Organotechnetium CompoundsPeptidesRadiopharmaceuticalsReceptors, SomatostatinTechnetiumAnimalsCell Line, TumorCell MembraneCell SurvivalHumansRatsOrganotechnetium CompoundsPeptidesRadiopharmaceuticalsReceptors, SomatostatinTechnetium99mTc radiopharmaceuticalsauger electronradionuclide therapy

Identifiers

PMID40333672
PMCPMC12029662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.